Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05202262 · ClinicalTrials.gov registry record · Phase 3
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 645
- Enrollment target
NCT05202262 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 645 participants.
The verdict
NCT05202262, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 645 participants
- Enrollment target
Study Summary
This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Interventions
- DRUG BFF MDI 320/9.6 μg
- DRUG BFF MDI 160/9.6 μg
- DRUG BD MDI 320 μg
- DRUG Open-label Symbicort TBH 320/9 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 645 participants |
| Start Date | 2022-01-12 |
| Est. Completion | 2025-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05202262
The ClinicalTrials.gov registry entry for NCT05202262 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 645 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BFF MDI 320/9.6 μg is the first listed.
NCT05202262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05202262 about?
NCT05202262 is a clinical study titled "A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)". This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.
What is the current status of trial NCT05202262?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 645 participants. The study started on 2022-01-12. Estimated completion is 2025-02-26.
What interventions are being tested in trial NCT05202262?
The interventions under investigation include: BFF MDI 320/9.6 μg (DRUG), BFF MDI 160/9.6 μg (DRUG), BD MDI 320 μg (DRUG), Open-label Symbicort TBH 320/9 μg (DRUG).
Who is sponsoring clinical trial NCT05202262?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.